Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Re: quality-of-life effects of prostate-specific antigen screening.

Taneja SS.

J Urol. 2013 Mar;189(3):899-900. doi: 10.1016/j.juro.2012.11.130. Epub 2012 Nov 21. No abstract available.

PMID:
23394636
2.

Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening.

Catalona WJ.

Eur Urol. 2013 Jan;63(1):180. doi: 10.1016/j.eururo.2012.10.030. No abstract available.

PMID:
23218492
3.

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.

Kobayashi T, Goto R, Ito K, Mitsumori K.

Eur J Surg Oncol. 2007 Aug;33(6):783-9. Epub 2007 Apr 3.

PMID:
17408910
5.

Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening.

Cooperberg MR.

Eur Urol. 2013 Jun;63(6):1130. doi: 10.1016/j.eururo.2013.03.019. No abstract available.

6.

The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less.

Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H.

J Urol. 2004 Feb;171(2 Pt 1):656-60.

PMID:
14713780
7.

Quality-of-life effects of prostate-specific antigen screening.

Nagata M, Tanimoto T, Kami M.

N Engl J Med. 2012 Nov 8;367(19):1861-2; author reply 1862. doi: 10.1056/NEJMc1211071#SA2. No abstract available.

PMID:
23134392
8.

Quality-of-life effects of prostate-specific antigen screening.

Haines IE.

N Engl J Med. 2012 Nov 8;367(19):1861; author reply 1862. doi: 10.1056/NEJMc1211071#SA1. No abstract available.

PMID:
23134391
10.

Economic evaluation of prostate cancer screening with prostate-specific antigen.

Imamura T, Yasunaga H.

Int J Urol. 2008 Apr;15(4):285-8. doi: 10.1111/j.1442-2042.2008.02013.x. Review.

11.

Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).

Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.

J Med Assoc Thai. 2006 Jan;89(1):37-42.

PMID:
16583579
12.

Prostate-specific antigen testing and prostate cancer screening.

Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H.

Prim Care. 2010 Sep;37(3):441-59, vii. doi: 10.1016/j.pop.2010.05.001. Review.

PMID:
20705192
13.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
14.

[Prostate cancer screening using prostate specific antigen (PSA) in Tokatsu Hospital--examination of lost-to-followup cases].

Shimizu N, Yamanaka H, Ichinose Y, Saitou Y.

Hinyokika Kiyo. 1998 Mar;44(3):155-8. Japanese.

15.

Elderly and prostate cancer screening.

Stamatiou KN.

Urol J. 2011 Spring;8(2):83-7. Review.

16.

Update on screening for prostate cancer with prostate-specific antigen.

Schmid HP, Riesen W, Prikler L.

Crit Rev Oncol Hematol. 2004 Apr;50(1):71-8. Review.

PMID:
15094160
18.

Impact of prostate cancer screening on health-related quality of life in at-risk families.

Cormier L, Guillemin F, Valéri A, Fournier G, Cussenot O, Mangin P, Litwin MS.

Urology. 2002 Jun;59(6):901-6.

PMID:
12031378
19.

The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis.

Albertsen PC.

Urology. 2010 Feb;75(2):399-405. doi: 10.1016/j.urology.2009.08.078. Epub 2009 Nov 22. Review.

PMID:
19931892
20.

Quality of life and economic considerations in the management of prostate cancer.

Turini M, Redaelli A, Gramegna P, Radice D.

Pharmacoeconomics. 2003;21(8):527-41. Review.

PMID:
12751912

Supplemental Content

Support Center